312 related articles for article (PubMed ID: 9594534)
1. [Therapy of dilated cardiomyopathies with and without inflammation].
Hufnagel G; Pankuweit S; Maisch B
Med Klin (Munich); 1998 Apr; 93(4):240-51. PubMed ID: 9594534
[TBL] [Abstract][Full Text] [Related]
2. Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins.
Maisch B; Hufnagel G; Kölsch S; Funck R; Richter A; Rupp H; Herzum M; Pankuweit S
Herz; 2004 Sep; 29(6):624-36. PubMed ID: 15912438
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive treatment for myocarditis and dilated cardiomyopathy.
Maisch B; Herzum M; Hufnagel G; Bethge C; Schönian U
Eur Heart J; 1995 Dec; 16 Suppl O():153-61. PubMed ID: 8682087
[TBL] [Abstract][Full Text] [Related]
4. Global biventricular dysfunction in patients with asymptomatic coronary artery disease may be caused by myocarditis.
Frustaci A; Chimenti C; Maseri A
Circulation; 1999 Mar; 99(10):1295-9. PubMed ID: 10077512
[TBL] [Abstract][Full Text] [Related]
5. [Etiopathogenetic differentiation of inflammatory cardiomyopathy. Immunosuppression and immunomodulation].
Kühl U; Pauschinger M; Schultheiss HP
Internist (Berl); 1997 Jun; 38(6):590-601. PubMed ID: 9265004
[No Abstract] [Full Text] [Related]
6. Myocarditis in children with dilated cardiomyopathy: incidence and outcome after dual therapy immunosuppression.
Kleinert S; Weintraub RG; Wilkinson JL; Chow CW
J Heart Lung Transplant; 1997 Dec; 16(12):1248-54. PubMed ID: 9436137
[TBL] [Abstract][Full Text] [Related]
7. Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis.
Camargo PR; Snitcowsky R; da Luz PL; Mazzieri R; Higuchi ML; Rati M; Stolf N; Ebaid M; Pileggi F
Pediatr Cardiol; 1995; 16(2):61-8. PubMed ID: 7784236
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory cardiomyopathy (myocarditis): which patients should be treated with anti-inflammatory therapy?
Parrillo JE
Circulation; 2001 Jul; 104(1):4-6. PubMed ID: 11435327
[No Abstract] [Full Text] [Related]
9. [Cardiotropic DNA viruses and bacteria in the pathogenesis of dilated cardiomyopathy with or without inflammation].
Pankuweit S; Hufnagel G; Eckhardt H; Herrmann H; Uttecht S; Maisch B
Med Klin (Munich); 1998 Apr; 93(4):223-8. PubMed ID: 9594531
[TBL] [Abstract][Full Text] [Related]
10. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results.
Hufnagel G; Pankuweit S; Richter A; Schönian U; Maisch B
Herz; 2000 May; 25(3):279-85. PubMed ID: 10904853
[TBL] [Abstract][Full Text] [Related]
11. Prognosis and treatment of cardiomyopathy and myocarditis.
O'Connell JB; Costanzo-Nordin MR; Engelmeier RS; Wallis DE; Robinson JA; Scanlon PJ
Heart Vessels Suppl; 1985; 1():175-9. PubMed ID: 3843581
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders.
Frustaci A; Chimenti C; Calabrese F; Pieroni M; Thiene G; Maseri A
Circulation; 2003 Feb; 107(6):857-63. PubMed ID: 12591756
[TBL] [Abstract][Full Text] [Related]
13. Dilated cardiomyopathy update: infectious-immune theory revisited.
Kawai C; Matsumori A
Heart Fail Rev; 2013 Nov; 18(6):703-14. PubMed ID: 23892949
[TBL] [Abstract][Full Text] [Related]
14. [Immunosuppressive therapy in myocarditis and dilated cardiomyopathy?].
Schultheiss HP
Internist (Berl); 1992 Oct; 33(10):650-62. PubMed ID: 1428684
[No Abstract] [Full Text] [Related]
15. [Immunosuppressive therapy in myocarditis and dilated cardiomyopathy--a critical analysis].
Schultheiss HP
Z Kardiol; 1989 Jun; 78(6):349-59. PubMed ID: 2667264
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory treatment strategies in inflammatory cardiomyopathy: current status and future perspectives.
Noutsias M; Pauschinger M; Poller WC; Schultheiss HP; Kühl U
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):37-51. PubMed ID: 15038412
[TBL] [Abstract][Full Text] [Related]
17. [Clinical picture and differential diagnosis of cardiomyopathy and myocarditis].
Sigusch HH; Reinhardt D; Figulla HR
Med Klin (Munich); 1998 Apr; 93(4):236-9. PubMed ID: 9594533
[TBL] [Abstract][Full Text] [Related]
18. Oleanolic acid modulates the immune-inflammatory response in mice with experimental autoimmune myocarditis and protects from cardiac injury. Therapeutic implications for the human disease.
Martín R; Cordova C; San Román JA; Gutierrez B; Cachofeiro V; Nieto ML
J Mol Cell Cardiol; 2014 Jul; 72():250-62. PubMed ID: 24732212
[TBL] [Abstract][Full Text] [Related]
19. Innovative drug treatments for viral and autoimmune myocarditis.
Anandasabapathy S; Frishman WH
J Clin Pharmacol; 1998 Apr; 38(4):295-308. PubMed ID: 9590456
[TBL] [Abstract][Full Text] [Related]
20. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results.
Wojnicz R; Nowalany-Kozielska E; Wojciechowska C; Glanowska G; Wilczewski P; Niklewski T; Zembala M; Polonski L; Rozek MM; Wodniecki J
Circulation; 2001 Jul; 104(1):39-45. PubMed ID: 11435335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
